A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...